Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in G12C-mutant advanced solid tumors: a first-in-human study

Journal:

Nature Communications

Published:

2026-03-12

DOI:

10.1038/s41467-026-69943-7

Affiliations:

22

Authors:

27

Go to article

Institutions	Authors	Share
Lilly, United States of America (USA)	7.000000	0.26
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	1.000000	0.04
Institute Gustave-Roussy (IGR), France	1.000000	0.04
Massachusetts General Hospital (MGH), United States of America (USA)	1.000000	0.04
Centre Léon Bérard (CLB), France	1.000000	0.04
National Cancer Center (NCC), South Korea	1.000000	0.04
Yale University, United States of America (USA)	1.000000	0.04
NYU Langone Health, United States of America (USA)	1.000000	0.04
Institut du Cancer de Montpellier (ICM), France	1.000000	0.04
Princess Margaret Cancer Centre, U of T, Canada	1.000000	0.04
UPMC Hillman Cancer Center (UPCI), United States of America (USA)	1.000000	0.04
Kansai Medical University Hospital, Japan	1.000000	0.04
Community Health Network, United States of America (USA)	1.000000	0.04
Virginia Cancer Specialists (VCS), United States of America (USA)	1.000000	0.04
Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole), France	1.000000	0.04
The START Center for Cancer Care, United States of America (USA)	1.000000	0.04
Fox Chase Cancer Center (FCCC), United States of America (USA)	1.000000	0.04
University of California, Irvine (UCI), United States of America (USA)	1.000000	0.04
National Cancer Center Hospital East, Japan	1.000000	0.04
National Cancer Center Hospital, Japan	1.000000	0.04
The Kinghorn Cancer Centre (TKCC), Australia	0.500000	0.02
University of New South Wales (UNSW Sydney), Australia	0.500000	0.02

Interested in Oncology and Carcinogenesis?